Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation
Sponsored by Novartis
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.